What are the mechanisms and benefits of Cosentyx in treating plaque psoriasis?
Cosentyx is a biologic medication that was developed to treat moderate to severe plaque psoriasis. It works by targeting the interleukin-17A (IL-17A) protein, which plays a role in the inflammation and immune response that contributes to psoriasis [1]. By inhibiting IL-17A, Cosentyx reduces the inflammation and swelling associated with plaque psoriasis, leading to clear or almost clear skin.
How does Cosentyx compare with other psoriasis treatments?
When compared to other biologic medications for plaque psoriasis, such as Humira and Stelara, Cosentyx has been shown to be effective in treating moderate to severe plaque psoriasis [2]. However, like all medications, Cosentyx is not suitable for everyone and can have side effects.
What are the efficacy and tolerability of Cosentyx for plaque psoriasis?
Efficacy trials have demonstrated that Cosentyx can achieve significant improvements in plaque psoriasis symptoms, with up to 80% of patients achieving clear or almost clear skin [3]. Common side effects of Cosentyx include upper respiratory tract infections, injection site reactions, and decreased white blood cell count [4]. While generally well-tolerated, some patients may experience rare but serious side effects, such as anaphylaxis or severe allergic reactions.
What are the long-term safety and efficacy of Cosentyx for plaque psoriasis?
Long-term studies have shown that Cosentyx is safe and effective in maintaining plaque psoriasis symptom improvement over time [5]. Additionally, a review of post-marketing surveillance data did not show any new or unusual safety concerns [6].
When can patients expect to see results with Cosentyx, and how often should it be administered?
Most patients notice improvements in their psoriasis symptoms within 16 weeks of starting Cosentyx, with maximum efficacy achieved within 24 weeks [7]. The recommended dosage is 300 mg administered subcutaneously every 4 weeks.
Overall, Cosentyx is a viable treatment option for moderate to severe plaque psoriasis, offering significant improvements in symptom control and quality of life for many patients.
Sources:
[1] http://www.drugpatentwatch.com/results.aspx?term=secukinumab&status=applied
[2] http://www.drugpatentwatch.com/results.aspx?term=secukinumab&status=approved
[3] https://www.cosentyx.com/en-us/research-clinical-trials/
[4] https://www.cosentyx.com/en-us/prescribing-information/
[5] https://www.cosentyx.com/en-us/research-clinical-trials/
[6] https://www.cosentyx.com/en-us/research-clinical-trials/
[7] https://www.cosentyx.com/en-us/prescribing-information/